Business
Cytophage Reports Successful Results and Data from Second EU Pilot Study for AviPhage
(TheNewswire) WINNIPEG, September 23, 2025 — TheNewswire - ...
About this update from Cytophage Technologies Ltd.
[{"type":"text","content":"Cytophage Reports Successful Results and Data from Second EU Pilot Study for AviPhage\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n WINNIPEG, September\n23, 2025\n \n\n\n\n —\n \n\n\n\n TheNewswire\n-\n \n\n\n\n Cytophage Technologies\nLtd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G)\ntoday announced positive results from its follow-up European pilot\nstudy of AviPhage, the Company’s proprietary poultry-based\nbacteriophage (phage) product for broiler chickens. These results\nreinforce the efficacy of AviPhage as a strong contender for\nantibiotic replacement in poultry farms, provide valuable new data\nthat builds upon the\n \n\n\n\n\n initial\npilot\n \n\n\n\n study\n \n\n\n findings, and\n \n\n\n\n mark\nanother milestone in advancing the product toward regulatory approval\nand commercial launch.\n \n\n\n\n\n\n The purpose of this follow-up study was\nto evaluate the efficacy of AviPhage on European poultry within a\nworking-barn setting. AviPhage-treated birds showed lower mortality\nand produced higher quality meat per bird compared to the control\ngroup birds.\n \n\n\n\n Overall,\nAviPhage’s broiler chickens matched or outperformed control group\nchickens on several key performance indicators, resulting in\nsubstantial improvement in the quality and quantity of the sellable\nmeat\n \n\n\n\n which can have a\ndirect economic impact for poultry producers.\n \n\n\n\n\n\n “The results from this study\nunderscore the real-world impact AviPhage can deliver – reducing\nreliance on antibiotics without sacrificing high quality food\nproduction. With this new data, we are well-positioned to accelerate\nregulatory engagement and commercial partnerships as we move closer to\nmarket introduction in Europe,”\n \n\n\n\n said Dr. Steven Theriault, CEO of Cytophage.\n \n\n\n\n\n\n Pilot Study Results -\nHighlights\n \n\n\n\n\n\n\n\n DECREASED\nMORTALITY\n \n\n\n\n : AviPhage\ntreatment reduced mortality by 35%, outperforming the control group\nand\n \n\n\n\n maintaining\n \n\n\n\n a\nmortality rate well below the European Food Safety Authority (EFSA)\nstandard for this breed. AviPhage-treated birds remained healthy\nthroughout the trial period.\n \n\n\n\n\n\n\n\n INCREASED SELLABLE\nMEAT\n \n\n\n\n : Each\nAviPhage-treat...